Explore the protective effect of Roxadustat on grafts in organ transplants

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030960

Enrollment

Unknown

Registered

2020-03-19

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end-stage renal disease

Interventions

experimental group:oral Roxadustat

control group:conventional therapy

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. 18-60 year old donors and recipients; 2. Indications for kidney transplant surgery; 3. Use DBD donor kidney for transplantation; 4. First kidney transplant; 5. BPAR, no contraindications to biopsy; 6. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with absolute contraindications for kidney transplantation; 2. Combined use in non-specified scopes, especially drugs that have a greater impact on the test results and affect the effectiveness and safety judgment; 3. Participate in other clinical trials; 4. Previous medical history of other organ transplants.

Design outcomes

Primary

Measure	Time frame
Delayed graft function;the degree of decrease of creatinine in early postoperative period (within 7 days);Incidence of AMR;	—

Countries

China

Contacts

Public ContactSun Qiquan

The Third Affiliated Hospital of Sun Yat-Sen University

sunqiq@mail.sysu.edu.cn+86 18922103587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026